Science

Akhil Santhosh: Primary efficacy and safety results from the AMALEE trial

Breast Cancer

Jan 15, 2025, 14:04

Akhil Santhosh: Primary efficacy and safety results from the AMALEE trial

Akhil Santhosh, Medical Oncologist at AIIMS Delhi, shared an article by Fatima Cardoso on X:

“Primary efficacy and safety results from the AMALEE trial evaluating 600 vs 400 mg starting doses of first-line ribociclib in patients with advanced BC.

400mg ribo has a better side effect profile but failed to meet non inferiority vs 600mg.”

Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer.

Authors: Fatima Cardoso, et al.

Akhil Santhosh: Primary efficacy and safety results from the AMALEE trial

More posts featuring Akhil Santhosh.

Abstract PD17-12 AIIMS DELHI Akhil Santhosh AMALEE trial Breast Cancer cancer Fatima Cardoso fight against cancer Global fight against cancer OncoDaily Oncology Ribociclib

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer